AI Article Synopsis
- Advances in gene editing may allow us to modify the human germline to prevent genetic conditions in unborn children.
- If effective, this could lead to clinical trials testing the technology in humans, necessitating careful observation of future generations with altered genes.
- The paper discusses the ethical concerns of monitoring these generations but argues that these issues can be managed through thoughtful trial design.
Article Abstract
As research involving gene editing continues to advance, we are headed in the direction of being able to modify the human germline. Should we reach a point where an argument can be made that the benefits of preventing unborn children and future generations from inheriting genetic conditions that cause tremendous suffering outweigh the risks associated with altering the human germline, the next step will be to design clinical trials using this technology in humans. These clinical trials will likely require careful follow-up and monitoring of future generations born with altered genes. This paper addresses some of the ethical issues raised by intergenerational monitoring and sets out to show that these issues can be avoided with careful consideration and clinical trial design.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/medethics-2020-106095 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessing Medicare's Coverage With Evidence Development Program.
Health Aff (Millwood)
January 2025
Reshma Ramachandran, Yale University.
The Centers for Medicare and Medicaid Services (CMS) coverage with evidence development (CED) program provides coverage for items and services not meeting Medicare's "reasonable and necessary" standard while requiring participation in clinical studies. As additional evidence is available, CMS may reconsider CED decisions. Of twenty-six items and services in the CED program since its 2005 inception, CMS has reconsidered coverage for ten (38 percent).
View Article and Find Full Text PDFA Core Outcome Set for Adult General ICU Patients.
Crit Care Med
January 2025
Department of Intensive Care, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
Objectives: Randomized clinical trials informing clinical practice (e.g., like large, pragmatic, and late-phase trials) should ideally mostly use harmonized outcomes that are important to patients, family members, clinicians, and researchers.
View Article and Find Full Text PDFPatient-Reported Outcome Scale for Allergic Rhinitis (AR-PRO): Development and Validation in China.
Int Forum Allergy Rhinol
January 2025
Department of Respiratory Diseases, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, China.
Background: Patient-reported outcomes (PROs) have become indispensable measures in allergic rhinitis (AR) clinical trials. However, there is currently no scale specifically designed for the Chinese population. This study aimed to develop and validate the patient-reported outcome scale for allergic rhinitis (AR-PRO) to provide a reliable tool for AR patients in China.
View Article and Find Full Text PDFDialysate and plasma meropenem concentrations in continuous intraperitoneal regimen during peritoneal-dialysis-related peritonitis.
PLoS One
January 2025
Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Background: A single dose of intraperitoneal (IP) meropenem is recommended for peritoneal-dialysis (PD)-related peritonitis stemming from extended-spectrum β-lactamase-producing organisms. However, data on IP meropenem is limited.
Methods: This prospective, descriptive study was conducted to examine plasma and dialysate meropenem levels during continuous IP meropenem administration in five patients with PD-related peritonitis.
Obesity is a metabolic disease that is marked by excessive fat accumulation and is objectively defined as a body mass index (BMI) ≥30 kg/m2. Obesity is associated with several other comorbidities, including psoriasis, which is a chronic autoimmune skin disease. Adipocytes produce pro-inflammatory signaling molecules, namely adipokines and classic cytokines, that drive increased inflammation axnd may contribute to the pro-inflammatory pathways driving psoriasis disease pathogenesis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!